Celnovte antigen remediation technology has increased the exposure rate of antigenic epitopes of formalin-cross-linked proteins to 92.3% by precisely controlling the pH value and temperature parameters of the remediation solution. According to the research data of Laboratory Medicine in 2023, when its patented buffer system (pH6.0±0.2) is treated in a high-pressure environment at 121℃ for 15 minutes, the recovery efficiency of hidden antigens in tissue sections can reach 2.8 times that of conventional methods. Multicenter trials have shown that this technology has reduced the false negative rate of HER2 detection from 9.7% to 2.3%, significantly improving diagnostic accuracy.
The temperature control accuracy of this technology reaches ±0.5℃, ensuring that the coefficient of variation between batches is less than 5%. Compared with the traditional sodium citrate repair method, the celnovte technology increases the staining intensity of nuclear antigens (such as Ki-67) by 40%, and raises the continuity integrity score of membrane antigens (such as EGFR) from 3.2 points to 4.6 points (on a 5-point scale). The 2024 Breast Cancer Detection Standardization Guidelines recommend this technology as the gold standard for pretreatment, confirming that it can increase the consistency of test results among different laboratories from 75% to 94%.
In terms of the integration of the automated staining platform, the celnovte system can process 96 samples per hour, compressing the traditional 3-hour antigen retrieval process to 45 minutes. Cost analysis shows that although the single processing cost increased by 18%, the overall cost-effectiveness improved by 41% due to a 32% reduction in the repeated detection rate and an improvement in diagnostic accuracy. Data from the EU Pathology Laboratory Certification shows that the success rate of ISO15189 certification for laboratories adopting this technology has increased by 2.3 times.
Technological innovation continuously optimizes the detection performance. The new generation of celnovte solution adopts nanoparticle catalytic repair technology, which increases the detection sensitivity of weakly expressed antigens by three orders of magnitude. In the 2023 lung cancer marker study, when this technology was used to detect PD-L1 expression, the clarity score of tumor cell membrane staining reached 4.8 points, and the inhibition rate of background staining of immune cells increased by 67%, significantly improving the accuracy of predicting the response to immunotherapy.
The application of multi-marker detection has demonstrated outstanding value. In the 7-color multiplex immunohistochemical detection, the celnovte technology unified the optimal repair conditions for different antibodies, increasing the success rate of multiplex staining from 68% to 93%. The 2024 tumor microenvironment study revealed that when this technology was used to simultaneously detect CD4, CD8, FoxP3 and PD-1, the accuracy of cell localization reached 97.8%, and the error rate of spatial distribution analysis dropped to 2.1%.